Enlivex Therapeutics Ltd witnessed a remarkable upswing in its stock value today, following its inclusion in the esteemed Zacks Rank #1 (Strong Buy) list. The Israeli-based macrophage reprogramming immunotherapy company experienced a surge in the Zacks Consensus Estimate for its current year earnings, boasting an impressive 19.1% increase over the past 60 days.
At the time of this publication, Enlivex Therapeutics Ltd stock (ENLV) has witnessed a surge.
Enlivex Therapeutics Ltd
Current Price: $1.81
Change : +0.40
Change (%): (28.01%)
Volume: 154.4K
Source: Tomorrow Events Market Data
As per the latest Zacks Consensus Estimate data, the following key metrics were reported:
– Target Price: $1.50
– 52 Week High-Low Range: $4.92 – $1.27
– 20 Day Average Volume: 21,777
– Beta Value: 1.10
– Market Capitalization: $26.18 million
– Dividend / Dividend Yield: NA
– Industry Sector: Medical – Drugs
– Industry Rank (Among Medical – Drugs Companies): 94/248 (Top 38%)
– Projected Earnings Per Share Growth (Q1): -3.23%
– Projected Earnings Per Share Growth (F1): 19.53%
– Price-to-Earnings Ratio (F1): NA
– Last Earnings Per Share Surprise: 13.95%
– Average Earnings Per Share Surprise (Last 4 Quarters): 1.73%
– Next Report Date: December 4, 2023
– Earnings Expected Surprise Percentage: 0.00%
The prestigious Zacks Rank #1 designation signifies a consensus among leading financial analysts that Enlivex Therapeutics Ltd is presently considered a “Strong Buy” prospect, underlining the company’s promising outlook and potential for robust growth.
Enlivex Therapeutics Ltd’s performance in the stock market over various time frames stands as follows:
– 5 Days: 33.83% increase
– 1 Month: 15.58% increase
– 3 Months: 37.53% decrease
– Year-to-Date (YTD): 54.79% decrease
– 1 Year: 58.60% decrease
Investors and stakeholders are closely monitoring the company’s trajectory as it navigates the dynamic landscape of the medical drugs industry.
Enlivex Therapeutics Ltd is a cutting-edge immunotherapy company based in Israel, specializing in macrophage reprogramming. The company’s innovative approach holds great promise for addressing a wide range of medical conditions and has garnered significant attention from both the scientific and investment communities.
For further information and updates on Enlivex Therapeutics Ltd, please visit their official website or consult with a licensed financial advisor.
